In:
Angewandte Chemie, Wiley, Vol. 128, No. 3 ( 2016-01-18), p. 1022-1026
Abstract:
Successful bench‐to‐bedside translation of nanomedicine relies heavily on the development of nanocarriers with superior therapeutic efficacy and high biocompatibility. However, the optimal strategy for improving one aspect often conflicts with the other. Herein, we report a tactic of designing tumor‐pH‐labile linkage‐bridged copolymers of clinically validated poly( d,l ‐lactide) and poly(ethylene glycol) (PEG‐ Dlink m ‐PDLLA) for safe and effective drug delivery. Upon arriving at the tumor site, PEG‐ Dlink m ‐PDLLA nanoparticles will lose the PEG layer and increase zeta potential by responding to tumor acidity, which significantly enhances cellular uptake and improves the in vivo tumor inhibition rate to 78.1 % in comparison to 47.8 % of the non‐responsive control. Furthermore, PEG‐ Dlink m ‐PDLLA nanoparticles show comparable biocompatibility with the clinically used PEG‐ b ‐PDLLA micelle. The improved therapeutic efficacy and safety demonstrate great promise for our strategy in future translational studies.
Type of Medium:
Online Resource
ISSN:
0044-8249
,
1521-3757
DOI:
10.1002/ange.201509507
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
505868-5
detail.hit.zdb_id:
506609-8
detail.hit.zdb_id:
514305-6
detail.hit.zdb_id:
505872-7
detail.hit.zdb_id:
1479266-7
detail.hit.zdb_id:
505867-3
detail.hit.zdb_id:
506259-7
